Disc Medicine, Inc. Common StockIRON
Scheduled
Disc Medicine, Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- Disc Medicine reported initial patient proof-of-concept data for DIX3405, an anti-TMPRSS6 monoclonal antibody, in polycythemia vera at the SOHO conference.
- DIX3405 increased hepcidin production, induced iron restriction, produced strong hematocrit control, reduced phlebotomy burden, and was associated with patients feeling better.
- The initial data showed 62% phlebotomy-free through the first 26 weeks and close to 78% during weeks 12 through 32.
- Safety and tolerability were described as strong, with management stating that the profile may be leading in the field.
- In the Apollo study of bitopertin in erythropoietic protoporphyria, enrollment reached 183 patients versus the planned 150, with two dropouts and 179 of the 181 patients who completed the study moving into either the open-label extension or the EAP.
- Apollo includes 75 patients per arm for 60 milligrams and placebo, compared with 25 patients per arm in Aurora, and introduces European sites with stratification by geography.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring